RxSight, Inc. (RXST) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +78.95%. A quarter ago, it was expected that this company would post a loss of $0.1 per share when it actually produced a loss of $0.08, delivering a surprise of +20%.Over the last four quarters, the company has surpas ...

In my search for small- and mid-cap stocks with the potential to become “10-baggers” over a 5–10 year horizon, I came across Green Brick Partners, Inc. ( GRBK ) — a vertically integrated homebuilderI am a corporate lawyer with an MBA and a long-standing interest in value investing. After spending 7 years practicing at several prestigious Wall Street and Silicon Valley law firms as a corporate transactional lawyer, I founded and have been operating my own boutique law firm for the last 10 years, focusing on ...

In my search for small- and mid-cap stocks with the potential to become “10-baggers” over a 5–10 year horizon, I came across Green Brick Partners, Inc. ( GRBK ) — a vertically integrated homebuilderI am a corporate lawyer with an MBA and a long-standing interest in value investing. After spending 7 years practicing at several prestigious Wall Street and Silicon Valley law firms as a corporate transactional lawyer, I founded and have been operating my own boutique law firm for the last 10 years, focusing on ...

Key insight: An unnamed bank tried to buy Comerica in September, weeks before the bank's board decided that Fifth Third would be the ideal acquirer, according to a new regulatory filing.What's at stake: At nearly $11 billion, the Fifth Third-Comerica deal is the largest of 2025.Forward look: Comerica CEO Curtis Farmer will receive $8.75 million per year as Fifth Third's vice chair, after which he will maintain the same compensation in his role as senior advisor.Once Comerica decided to sell itself to anothe ...

Lantronix, Inc. (LTRX) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +33.33%. A quarter ago, it was expected that this company would post earnings of $0.01 per share when it actually produced earnings of $0.01, delivering no surprise.Over the last four quarters, the company has surp ...

EnerSys (ENS) came out with quarterly earnings of $2.56 per share, beating the Zacks Consensus Estimate of $2.36 per share. This compares to earnings of $2.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +8.47%. A quarter ago, it was expected that this maker of industrial batteries would post earnings of $2.05 per share when it actually produced earnings of $2.08, delivering a surprise of +1.46%.Over the last four quarters, ...

Zevia (ZVIA) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +33.33%. A quarter ago, it was expected that this stevia-sweetened soda maker would post a loss of $0.05 per share when it actually produced a loss of $0.01, delivering a surprise of +80%.Over the last four quarters, the company h ...

Core Points - Evommune, Inc. has priced its initial public offering (IPO) at $16.00 per share, offering 9,375,000 shares, with expected gross proceeds of $150 million [1][2] - The shares are set to begin trading on the New York Stock Exchange under the symbol "EVMN" on November 6, 2025, with the offering expected to close on November 7, 2025 [2] - The company is focused on developing innovative therapies targeting chronic inflammatory diseases, aiming to improve patients' daily lives and address the limitations of existing therapies [5] Company Overview - Evommune, Inc. is a clinical-stage biotechnology company dedicated to creating therapies that address key drivers of chronic inflammatory diseases [5] - The company's mission includes preventing long-term effects of uncontrolled inflammation through a portfolio of differentiated product candidates [5] Offering Details - The IPO includes a 30-day option for underwriters to purchase an additional 1,406,250 shares at the initial offering price [1] - Joint book-running managers for the offering include Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor [2]

Nov 5, 2025 7:45 PM Eastern Standard Time EL SEGUNDO, Calif.--(BUSINESS WIRE)--Mattel, Inc. (NASDAQ: MAT) ("Mattel†or the "Company†) announced today the pricing of its underwritten public offering (the "Offering†) of $600,000,000 aggregate principal amount of 5.000% Senior Notes due 2030 (the "Notes†). The Notes will be senior, unsecured obligations of the Company and will mature on November 17, 2030. The Offering is expected to close on or about November 17, 2025, subject to the satisfaction of custo ...

Core Insights - Enovix Corporation reported a quarterly loss of $0.14 per share, which was better than the Zacks Consensus Estimate of a loss of $0.16, marking an earnings surprise of +12.50% [1] - The company achieved revenues of $7.99 million for the quarter ended September 2025, slightly missing the Zacks Consensus Estimate by 1.09%, but showing significant growth from $4.32 million a year ago [2] - Enovix shares have increased by approximately 2.2% since the beginning of the year, underperforming compared to the S&P 500's gain of 15.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.15 on revenues of $12.8 million, and for the current fiscal year, it is -$0.58 on revenues of $33.01 million [7] - The estimate revisions trend for Enovix Corporation was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Electronics - Miscellaneous Products industry, to which Enovix belongs, is currently ranked in the top 23% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]